Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While international sales and product launches are strong, U.S. sales and rentals have declined. The company's financial health remains solid with a strong cash position, but increased losses and negative EBITDA raise concerns. The Q&A session reveals positive feedback on new products but highlights uncertainties in market penetration and cost pressures. With no clear market cap provided, the overall sentiment suggests a neutral stock price movement in the short term, as positive international growth is offset by domestic challenges.
Key Financial Performance
Total Revenue $85.1 million, representing 3.4% year-over-year growth. Growth driven by continued strength in international markets and channel mix pressure in the U.S. market.
Unit Volumes 14% year-over-year growth. Growth attributed to the structural conversion towards portable oxygen concentrators (POCs) in the U.S. market.
U.S. Sales $34.7 million, down 5% year-over-year. Decline due to channel mix shift and reduced patient counts.
International Sales $37.7 million, up 18% year-over-year. Growth driven by strong commercial execution, key HME partnerships, international tenders, and expansion into new geographies.
U.S. Rentals $12.7 million, down 8% year-over-year. Decline attributed to channel mix shift and reduced patient counts.
Adjusted Gross Margin 44.7%, an increase of 30 basis points from 44.4% in the prior year period. Improvement due to cost improvements.
Adjusted Operating Expenses $43 million, an increase of 5.1% from $40.9 million in the prior year period. Increase driven by investments in R&D, clinical evidence generation, and commercial organization.
Adjusted R&D Expense $4.1 million, an increase of $0.9 million versus the prior year. Increase due to investments in clinical evidence generation and new product development.
Adjusted SG&A Expense $39 million, an increase of 3.1% versus the prior year. Increase driven by commercial organization investment and timing of advertising spend.
GAAP Net Loss $8.3 million compared to $6.2 million in the prior year period. Increase in losses due to planned incremental R&D and commercial investments.
Adjusted Net Loss $4 million compared to $2.9 million in the prior year. Increase in losses due to planned incremental R&D and commercial investments.
Adjusted EBITDA Negative $1.4 million compared to approximately breakeven in the prior year period. Decline due to timing of planned incremental R&D and commercial investments.
Cash Position $111.5 million in cash, cash equivalents, marketable securities, and restricted cash with 0 debt outstanding. Strong cash position maintained.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Aurora CPAP mask family: Launched in the U.S. with positive early feedback. Targeting the $2.2 billion U.S. CPAP mask market, growing at a high single-digit rate. Clinical trials showed preference over existing masks. Revenue contribution expected to grow in the second half of 2026.
Rove 6 portable oxygen concentrator: Launched in Brazil as part of international expansion. Designed for local markets and builds on established distribution relationships.
Simeox: Began patient enrollment in IMPACTS-200 reimbursement trial. Targets a $500 million U.S. market in non-cystic fibrosis bronchiectasis. Offers clinical differentiation and recurring revenue potential.
International sales: Revenue of $37.7 million, up 18% year-over-year. Expanded into Eastern Europe, Latin America, and Asia Pacific. Strong performance driven by key HME partnerships and new geography entries.
Revenue growth: Q1 revenue of $85.1 million, a 3.4% year-over-year increase. International sales offset lower U.S. sales.
Adjusted gross margin: Improved to 44.7%, up 30 basis points year-over-year due to cost improvements.
Cash position: Ended Q1 with $111.5 million in cash and no debt. Executed stock repurchase program, buying back 298,000 shares for $1.9 million.
Portfolio expansion: Expanded addressable market from $400 million to $3.4 billion by entering oxygen therapy, sleep therapy, airway clearance, and digital health.
Leadership changes: Appointed new CFO, Chief Marketing Officer, and Board member to strengthen strategic and operational capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
U.S. Sales Decline: U.S. sales were down 5% year-over-year, driven by a continued channel mix shift and reduced patient counts, which could impact revenue growth.
Direct-to-Consumer and Rental Channel Pressure: The structural conversion of the U.S. market towards portable oxygen concentrators (POCs) has created headwinds in the direct-to-consumer and rental channels, potentially affecting revenue and operational efficiency.
Increased Operating Expenses: Adjusted operating expenses increased by 5.1% year-over-year, driven by higher R&D and SG&A costs, which could pressure profitability.
Net Loss Increase: GAAP net loss increased to $8.3 million from $6.2 million in the prior year, and adjusted net loss also widened, reflecting the impact of planned incremental investments.
Profitability Challenges: Adjusted EBITDA was negative $1.4 million in the first quarter, compared to approximately breakeven in the prior year, indicating challenges in achieving profitability.
Market Competition and Pricing Pressure: The company faces pricing pressure in its core POC business, which could impact its ability to maintain premium positioning and margins.
Reimbursement and Regulatory Risks for Simeox: The success of the Simeox device depends on building a robust evidence base to secure reimbursement from CMS and private payers, which introduces regulatory and market risks.
International Expansion Risks: While international sales grew, entering new geographies like Brazil and expanding into regions such as Eastern Europe and Latin America carry risks related to market penetration and operational execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Reaffirmed revenue guidance of $366 million to $373 million, representing approximately 6% growth at the midpoint.
Second Quarter 2026 Revenue Outlook: Expected revenue in the range of $94 million to $97 million, reflecting approximately 3.5% growth at the midpoint compared to Q2 2025.
Profitability Outlook: Committed to driving adjusted EBITDA improvement for the full year 2026, following positive adjusted EBITDA achieved in 2025.
Aurora CPAP Mask Revenue Contribution: Expected to be more back half weighted as momentum builds in the U.S. CPAP mask market, estimated at $2.2 billion and growing at a high single-digit rate.
Simeox Reimbursement Trial: Began patient enrollment in IMPACTS-200 trial to build evidence for CMS and private payer reimbursement. U.S. opportunity estimated at $500 million TAM in non-cystic fibrosis bronchiectasis, growing at a high single-digit rate.
International Expansion: Continued expansion into new geographies, including Brazil, Eastern Europe, Latin America, and Asia Pacific, with products tailored for these markets.
Product Launch Strategy: Committed to at least one new product launch each year, focusing on higher-growth markets with higher gross margin profiles.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: During the quarter, Inogen began execution of its stock repurchase program. Approximately 298,000 shares of common stock were purchased for nearly $1.9 million. The company believes its stock is undervalued relative to its fundamentals and strategic opportunities. Returning capital to shareholders while investing in growth is a priority, and the company intends to continue this approach thoughtfully over the course of the program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you frame the size of the Brazilian COPD market and the current state of POC penetration? Is this largely an oxygen tank replacement opportunity or are you stepping into an established POC market?
A:The size of the Brazilian COPD market has not been quantified. It is an emerging market opportunity with an existing population of oxygen tanks and POCs. Inogen is entering as a premium brand with partnerships with local HMEs familiar with the brand. Growth is expected over time with market access.
Q:What drove the steeper decline in net rental patients at the end of the first quarter, and how should we think about this channel through the remainder of the year?
A:The decline is due to the shift from oxygen tanks to POCs in the U.S., impacting both DTC and rental patients while creating a tailwind for B2B channels. Pressure on the rental channel is expected to continue throughout the year, but total U.S. growth is anticipated by year-end.
Q:How is the early 2026 Voxi 5 ramp tracking against expectations, and are there pull-through benefits with HMEs bundling Voxi 5 alongside the POC?
A:The early ramp of Voxi 5 is tracking well with expectations. Feedback has been positive, and pull-through and attachment rates are aligning with long-term expectations.
Q:What is the impact of elevated oil prices, and do you have any sales in the Middle East?
A:Elevated oil prices have not had a significant impact yet, though there could be implications for logistics and petroleum-based components if prices remain high throughout the year. Inogen has business in the Middle East, but the majority of international business comes from Europe. There has been no negative impact so far.
Q:Could you provide an update on the CPAP mask launch and customer feedback?
A:The Aurora mask launch has been successful, exceeding expectations. Clinical data supports patient preference and quality, leading to high reorder rates from customers, indicating strong early adoption.
Q:Why was the adjusted net loss flat or down from last year, and why wasn't there more leverage or cost savings from OpEx?
A:The flat or down adjusted net loss is due to accelerated clinical evidence investments, particularly around Simeox, and earlier advertising spend to generate business for the back half of the year. Gross margin expansion is a critical focus to offset market mix pressures.
Q:Is the advertising spending geared towards the consumer business or the B2B side?
A:Advertising spending has historically been geared towards the direct-to-consumer business but is now being broadened to include HCPs and HMEs. The strategy is evolving into a more sophisticated marketing project.
Q:Review of Unclear Management Responses
A:Management avoided directly quantifying the size of the Brazilian COPD market and provided vague language about the impact of elevated oil prices, stating it is not significant yet but could become impactful if prolonged. Additionally, the response about adjusted net loss lacked detailed clarity on why there wasn't more leverage or cost savings from OpEx.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brazil
COPD patient
CPAP mask
Chief
HME partner
Inogen CFO
Latin America
Officer
POC
RD
Simeox
bronchiectasis
category
digit rate
discussion
evidence base
exchange
expansion
foundation
home
increase period
industry
infrastructure brand
life
margin profile
market COPD
meeting
mix pressure
opportunity
oxygen therapy
population
statement expectation
stock
therapist
therapy sleep
today Inogen
INGN Transcript
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed outlook. While international sales and product launches are strong, U.S. sales and rentals have declined. The company's financial health remains solid with a strong cash position, but increased losses and negative EBITDA raise concerns. The Q&A session reveals positive feedback on new products but highlights uncertainties in market penetration and cost pressures. With no clear market cap provided, the overall sentiment suggests a neutral stock price movement in the short term, as positive international growth is offset by domestic challenges.
Inogen, Inc. (INGN) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reveals positive elements: a raised EBITDA guidance, international revenue growth, and successful product launches. Despite some declines in U.S. sales and gross margins, the overall financial health is improving with a reduced net loss and strong cash position. The Q&A highlights optimism for future growth, particularly in the POC and mask markets, despite management's reluctance to provide specific guidance. Given these factors, a positive stock price movement is expected, driven by international expansion and product innovation.
Inogen, Inc. (INGN) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reflects mixed signals: a 4% revenue increase and improved profitability are positive, but declining margins, rental revenue, and unclear guidance on key products like Simeox are concerning. Additionally, potential legal risks and increased operating expenses could strain financials. The Q&A section highlights international growth potential but lacks clarity on U.S. expansion. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Inogen, Inc. (INGN) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call reflects a positive sentiment due to the collaboration with UL Medical, strong demand for Voxi 5, and improved financial metrics like reduced net loss and positive cash flow. However, concerns about declining gross margins and lack of specific guidance on Simeox's launch and Voxi 5's pricing slightly temper the outlook. The positive adjusted EBITDA and expected double-digit growth in Q4, alongside the strategic partnership, suggest a positive stock price movement over the next two weeks.
INGN Slides
INGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
